{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.67","upperLimit":"83.33","value":"50.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"}],"units":"Participants"}],"description":"Platelet response was defined as a platelet count of ≥ 50 x 10⁹/L with no rescue medication use for ITP in the past 4 weeks.\n\nMonthly platelet response was calculated based on the median platelet count during each month. For each participant, the percentage of time with platelet response during the first 6 months was calculated as the number of months a platelet response was observed divided by the total number of months response was assessed.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years. The starting dose was 1 µg/kg titrated in 1 µg/kg increments up to a maximum of 10 µg/kg to reach a target platelet count ≥ 50 x 10⁹/L.","id":"OG000","title":"Romiplostim"}],"paramType":"MEDIAN","populationDescription":"The efficacy analysis set included all enrolled participants who received at least 1 dose of romiplostim","reportingStatus":"POSTED","timeFrame":"Week 2 to Month 6, platelet response was assessed every week.","title":"Percentage of Time With a Platelet Response During the First 6 Months of Treatment","type":"PRIMARY","unitOfMeasure":"percentage of time"}